Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate the efficacy of GDC-0199 and rituximab (GDC-0199+R) compared with bendamustine and rituximab (BR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) as measured by investigator-assessed progression-free survival (PFS). While the primary efficacy endpoint is investigator-assessed PFS, PFS based on IRC assessments will also be analyzed to support the primary analysis. In the United States, IRC-assessed PFS will be the basis for regulatory decisions.
Critère d'inclusion
- Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)